Ublituximab + Ibrutinib in Select B-cell Malignancies
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in
combination with Ibrutinib in patients with advanced hematologic malignancies.